Studies real-world safety of ozanimod in people with ulcerative colitis
Observes safety of ozanimod in adults with moderate to severe ulcerative colitis.
Plain-language title generated from the registry record
Registry title: A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Bristol-Myers Squibb YHSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT06073873
- Record updated
- 22 August 2024
- Original description
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.Read full original descriptionShow less
Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.
Inclusion: Adult participants 19 years of age or older; Participants who will receive ozanimod according to the approved label after enrollment; Participants who sign the informed consent form voluntarily.
Exclusion: Participants for whom ozanimod is contraindicated as clarified in Korean prescribing information approved by Ministry of Food and Drug Safety; Participants who are prescribed ozanimod for therapeutic indications not approved in Korea.